

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services



MLN Matters® Number: MM9746

Related Change Request (CR) #: CR 9746

Related CR Release Date: October 28, 2016

Effective Date: January 1, 2017

Related CR Transmittal #: R159DEMO

Implementation Date: January 3, 2017

IVIG Demonstration: Payment Update for 2017

Note: This article was revised on August 29, 2017, to add a reference to a related MLN Matters Article, [SE17008](#). SE17008 reminds suppliers of the scheduled end date for the IVIG Demonstration. It also reminds physicians, who may treat patients with primary immune deficiency syndrome that use IVIG, of the end date for the IVIG Demonstration. All other information remains unchanged.

Provider Types Affected

This MLN Matters® Article is intended for suppliers submitting claims to Durable Medical Equipment Medicare Administrative Contractors (DME MACs) for Intravenous Immune Globulin (IVIG) drugs and services provided to Medicare beneficiaries under the IVIG demonstration using code Q2502.

Provider Action Needed

Change Request (CR) 9746 specifies the IVIG Demonstration payment rate for services rendered on or after January 1, 2017 through September 30, 2017 for code Q2052 is \$354.60. Since the demonstration ends on September 30, 2017, no payment will be made for services rendered after that date. Make sure that your billing staffs are aware of this update.

Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2015 American Medical Association. All rights reserved.

Background

The “Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012,” authorizes a three-year demonstration under Part B of Title XVIII of the Social Security Act (the Act) to evaluate the benefits of providing payment for items and services needed for the in-home administration of IVIG for the treatment of Primary Immune Deficiency Disease (PIDD).

CR 9254 established the payment rate under the demonstration for 2016. CR9746 notifies providers that the payment rate for Q2052: “Services, Supplies and Accessories Used in the Home under the Medicare IVIG Demonstration” for January 1-September 30, 2017 shall be \$354.60.

Additional Information

The official instruction, CR9746 issued to your MAC regarding this change is available at <https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R159DEMO.pdf>.

If you have any questions, please contact your MAC at their toll-free number. That number is available at <https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/>.

The MLN Matters article related to CR9254 is available at <https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/MM9254.pdf>.

Document History

Date of Change	Description
August 29, 2017	The article was revised on August 29, 2017, to add a reference to a related MLN Matters Article, SE17008 . SE17008 reminds suppliers of the scheduled end date for the IVIG Demonstration. It also reminds physicians, who may treat patients with primary immune deficiency syndrome that use IVIG, of the end date for the IVIG Demonstration.
October 28, 2016	Initial article released

Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2015 American Medical Association. All rights reserved.